retatrutide what is it clinical trial Eli Lilly's Phase 3 studies investigating retatrutide, the "triple-G" agonist, have found that long-term use can achieve substantial weight loss. Read about the work via the link in the comments VisualAbstract: Retatrutide reduces body weight

March 24, 2024 JAMA Study Links Ozempic to Increased Risk of Bowel Injuries Another study has linked the use of Ozempic, a GLP-1-like peptide agonist, to bowel injuries

Physiological weight loss can help decrease metabolic risk factors and is effective in managing several diseases

"Clinicians know that most of their GLP-1 patients will eventually stop the medication, and without new habits the weight tends to come back," said Geoff Cook, CEO of Noom

Overall, the effects of these compounds on fat metabolism, body mass index, lean mass, and insulin sensitivity might show changes in body weight on long-term treatment, yet they are less likely to offer the same results as GLP-1 patches

Dosing guidance is in the how to dose semaglutide guide

Optimize GLP-1 Results with bistroMD Chef-prepared, gourmet meals designed to make your GLP-1 lifestyle easyand incredibly effective